Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Prestige Brands rolls out FiberChoice, BC Powder brand extensions; subsidiary cross-selling aids Atrium Innovations; Dr. Reddy’s downplays switch outlook; Nu Skin gears up for ageLOC weight management launch; more Sales & Earnings In Brief.
You may also be interested in...
Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Rapidly Growing Prestige Brands Still Positioned For OTC Pickups
The company says it successfully integrated the OTC portfolio acquired from GlaxoSmithKline and is using free cash flow to trim its debt load in the wake of the debt-financed $660 million deal. Prestige reported Q1 net sales up 54.7%, including 4.2% organic growth in OTC health care.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.